Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).

[1]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[2]  John R. Mackey,et al.  Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .

[3]  J. Baselga,et al.  Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study , 2009, Clinical Cancer Research.

[4]  Narine Sarvazyan,et al.  Anthracycline cardiotoxicity: from bench to bedside. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Vacek,et al.  Anthracycline-Induced Cardiomyopathy , 2008, Postgraduate medicine.

[6]  Leszek Wojnowski,et al.  Dystrophin‐deficiency increases the susceptibility to doxorubicin‐induced cardiotoxicity , 2007, European journal of heart failure.

[7]  E. D. de Vries,et al.  111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. , 2007, European journal of cancer.

[8]  F. Holmes,et al.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Gianni,et al.  Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies , 2006, Journal of Pharmacology and Experimental Therapeutics.

[10]  G. Batist,et al.  Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis , 2006, Anti-cancer drugs.

[11]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[12]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[13]  C. Shapiro,et al.  Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. LeBrasseur,et al.  Cardiac Endothelial Cells Regulate Reactive Oxygen Species-induced Cardiomyocyte Apoptosis through Neuregulin-1β/erbB4 Signaling* , 2004, Journal of Biological Chemistry.

[16]  C. Bennett,et al.  Pharmacoeconomics of liposomal anthracycline therapy. , 2004, Seminars in oncology.

[17]  S. Chan,et al.  Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[19]  R. Schwartz,et al.  Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Wallwiener,et al.  Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. , 2004, European journal of cancer.

[21]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  D. Crivellari,et al.  New oral drugs in older patients: a review of idarubicin in elderly patients. , 2004, Critical reviews in oncology/hematology.

[23]  Carmen Birchmeier,et al.  ErbB2 pathways in heart and neural diseases. , 2003, Trends in cardiovascular medicine.

[24]  M. Drummond,et al.  A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. Palumbo,et al.  New developments and treatment in multiple myeloma: new drugs in the treatment of multiple myeloma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Ducreux,et al.  Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  L Biganzoli,et al.  EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  E. Winer,et al.  Liposomal anthracyclines for breast cancer. , 2001, Seminars in oncology.

[29]  G. Sledge.  The continuing problem of cardiac toxicity , 2001 .

[30]  A. Janoff,et al.  Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate) , 2001 .

[31]  N. Jaffe,et al.  Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. , 2001, Oncology reports.

[32]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[33]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[35]  E. Perez.  Doxorubicin and Paclitaxel in the Treatment of Advanced Breast Cancer: Efficacy and Cardiac Considerations , 2001, Cancer investigation.

[36]  D. Jain,et al.  Cardiotoxicity of doxorubicin and other anthracycline derivatives , 2000, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[37]  V. Bramwell,et al.  Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. , 1999, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC.

[38]  P. Dombernowsky,et al.  Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[40]  D. Opel,et al.  Neuregulins Promote Survival and Growth of Cardiac Myocytes , 1998, The Journal of Biological Chemistry.

[41]  S. Johnson,et al.  Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. , 1997, Blood reviews.

[42]  A. Howell,et al.  Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Swain,et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Swain,et al.  Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Hochster,et al.  Cardiotoxicity and cardioprotection during chemotherapy. , 1995, Current opinion in oncology.

[46]  N. Habboubi,et al.  Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. , 1993, Cancer treatment reviews.

[47]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[48]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[49]  M. Lishner,et al.  Reduced cardiotoxicity of doxorubicin by a 6‐hour infusion regimen. A prospective randomized evaluation , 1990, Cancer.

[50]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[51]  A. Ross,et al.  Acute arrhythmogenicity of doxorubicin administration , 1987, Cancer.

[52]  N. Mulder,et al.  A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  N. Dubin,et al.  Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. , 1985, The American journal of medicine.

[54]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[55]  D. Thiele,et al.  Sudden death during doxorubicin administration , 1979, Cancer.

[56]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[57]  Daniels,et al.  Clinical spectrum of anthracycline antibiotic cardiotoxicity. , 1978, Cancer treatment reports.

[58]  S. Jones,et al.  Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer , 1975, Cancer.

[59]  A. Wolff,et al.  Predicting Cancer Therapy-Induced Cardiotoxicity , 2002, Drug safety.

[60]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[61]  G. Hortobagyi.  Anthracyclines in the treatment of cancer. An overview. , 1997, Drugs.

[62]  M. Bates,et al.  A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer. , 1997, Clinical therapeutics.

[63]  E K Rowinsky,et al.  Paclitaxel (taxol) , 1995, The New England journal of medicine.

[64]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .